Shanghai RAAS Blood Products Co Ltd SZSE:002252:
Q1 NET PROFIT DOWN 44.2% Y/Y
Shanghai RAAS Blood Products Q1 Net Profit Down 44.2% Y/Y
Earlier from Shanghai Raas Blood Products Co., Ltd. Class A
- Shanghai RAAS Blood Products: Revenue and profit declined, but plasma expansion and innovation drive future growth
- Shanghai RAAS Blood Products 2025 Net Profit Down 28.1%
- Shanghai RAAS Blood Products: Net profit dropped 26% on flat revenue, with major buybacks and clinical trial advances
- Shanghai RAAS Blood Products Q3 Net Profit Down 26.2% Y/Y